# US 10,501,433 B2 · Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,501,433 B2 - Document ID: US10501433B2 - Status: Granted - Kind: B2 - Application number: 15/948,821 - Filed: 2018-04-09 - Published: 2019-02-14 - Granted: 2019-12-10 - Earliest claimed: 2013-09-26 - Assignees: CHDI Foundation, Inc. - Applicants: CHDI Foundation, Inc. - Inventors: Celia Dominguez; Leticia Toledo-Sherman; Michael Prime; William Mitchell; Naomi Went - Web page: https://patentgrep.com/patent/US10501433B2 ## CPC - C07D 327/06: Six-membered rings - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07D 211/72: with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms - C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom - C07D 233/70: One oxygen atom - C07D 235/26: Oxygen atoms - C07D 263/38: attached in position 2 - C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2 - C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring - C07D 311/02: ortho- or peri-condensed with carbocyclic rings or ring systems - C07D 311/04: Benzo[b]pyrans, not hydrogenated in the carbocyclic ring - C07D 317/46: condensed with one six-membered ring - C07D 317/50: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring - C07D 317/62: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring - C07D 319/16: condensed with one six-membered ring - C07D 319/18: Ethylenedioxybenzenes, not substituted on the hetero ring - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. ## Claims ### Claim 1 A method of inhibiting the progression of, slowing or arresting the development of clinical symptoms of, or causing the regression of clinical symptoms of a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof, by inhibiting Kynurenine 3-mono-oxygenase activity, and wherein the condition or disorder is Huntington's Disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, cerebral ischemia, damage to the spinal cord, dementia, senile dementia, AIDS-dementia complex, or AIDS-induced encephalopathy. ### Claim 2 (depends on 1) The method of claim 1, wherein said condition or disorder is Huntington's Disease. ### Claim 3 A method of inhibiting the progression of, slowing or arresting the development of clinical symptoms of, or causing the regression of clinical symptoms of a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, by inhibiting Kynurenine 3-mono-oxygenase activity, and wherein the condition or disorder is Huntington's Disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, cerebral ischemia, damage to the spinal cord, dementia, senile dementia, AIDS-dementia complex, or AIDS-induced encephalopathy. ### Claim 4 (depends on 3) The method of claim 3, wherein said condition or disorder is Huntington's Disease.